节点文献
Graves病131I治疗后一年内缓解和早发甲减患者血清IL-18和TRAb的变化分析
Changes of the Serum IL-18 and TRAb in Patients with Graves’ Disease after 131I Treatment Within One Year
【摘要】 探讨131I治疗后一年内GD患者甲减的免疫功能状态的改变。采用CLIA、IRMA和EIA方法,监测41例GD患者131I治疗前后血清白细胞介素-18(IL-18)、促甲状腺素受体抗体(TRAb)、TPOAb的含量和甲状腺重量(TDW)变化。41例GD患者分为甲减组13例和缓解组28例。结果表明治疗前两组GD患者血清IL-18和TRAb水平明显升高,与对照组比较均有显著性差异(P<0.01,P<0.05),两组间比较,血清FT3、FT4、sTSH、TDW和131I剂量均无显著性差异(P>0.05)。治疗后两组血清IL-18明显下降,甲减组血清sTSH升高明显(P<0.01),而缓解组TDW明显减少(P<0.05)。两组患者治疗后的TRAb水平仍然较高(P<0.05)。IL-18与FT3、FT4和TDW呈正相关(r=0.372,P<0.01;r=0.312,P<0.01;r=0.371,P<0.01),与sTSH呈负相关(r=-0.224,P<0.01)。甲减组TPOAb升高的病例治疗前为4/13,治疗后为6/13;缓解组治疗前为10/28,治疗后为12/28。131I治疗后6~12个月内辐射对患者免疫系统的调控产生的直接影响较小,血IL-18含量变化如结合TRAb、TPOAb指标了解甲状腺Th1/Th2型免疫应答状态,对疗效观察和预后判断有阶段性指导作用。
【Abstract】 To investigate immunological function change in Graves’ disease(GD) patients with hypothyroidism within one year after 131I treatment,and evaluate the relationship between the 131I theatment and autoimmune thyroid disease.Serum levels of IL-18,TRAb and TPOAb in 41 patients with GD were determined by EIA,IRMA and CLIA,thyroid weight(TDW) were measured by B ultrasonic instrument.The patients were divided into two groups based on whether appear the early hypothyroidism after 131I treatment during 6~12 months graded as: the hypothyroidism group in 13 and the recovery group in 28;25 healthy people as control group.Results showed that the serum levels of IL-18 and TRAb in hypothyroidism group and recovery group were significantly increased before 131I treatment compared with control group(P<0.05).Between hypothyroidism and recovery groups,the levels of serum FT3,FT4,sTSH,TDW and 131I dosage were not significant differences(P>0.05).The serum levels of IL-18 in two groups were decreased(P<0.05),the serum sTSH levels in hypothyroidism group were elevated(P<0.01),TDW in recovery group were reduced(P<0.05),and the TRAb levels in two groups were still high after 131I treatment(P<0.05).Positive correlations between IL-18 and FT3,FT4,TDW(r=0.372 P<0.01,r=0.312 P<0.01,r=0.371 P<0.01),and negative correlations between IL-18 and sTSH were noted in GD(r=-0.224 P<0.01).Ratio of patients with serum TPOAb levels elevated in the hypothyroidism group were 4/13 before 131I therapy and 6/13 after therapy,and in the recovery group were 10/28 before therapy and 12/28 after therapy.These data suggest that radiation has a little influence on GD patients for adjusting immune system during 6~12 months after 131I treatment.The changes of serum IL-18 and combine with serum TRAb and TPOAb might be valuable implication for assessing the effect and prognosis of 131I treatment in patients with GD hyperthyroidism.
【Key words】 Graves’ disese; 131I treatment; Hypothyroidism; Interleukin-18;
- 【文献出处】 标记免疫分析与临床 ,Labeled Immunoassays and Clinical Medicine , 编辑部邮箱 ,2007年02期
- 【分类号】R581.1
- 【被引频次】2
- 【下载频次】87